ADVERTISEMENT
A phase II study of resection followed by capecitabine plus oxaliplatin for liver metastasis of colorectal cancer (REX study): Final analysis
Background
Surgical resection has been accepted as the standard therapy for colorectal cancer liver metastases (CRLM), however, high recurrence incidence even after curative resection remains an unsolved problem. Although both mFOLFOX6 (modified infusional fluorouracil, leucovorin, and oxaliplatin) and CapeOx (Capecitabine plus oxaliplatin) are standard therapies for stage III colorectal cancer as adjuvant setting, there was no established adjuvant chemotherapy for CRLM. mFOLFOX6 conferred disease free survival (DFS) but not overall survival (OS) benefit in JCOG 0603 (Kanemitsu Y, et al. J Clin Oncol. 2021 Dec 1;39(34):3789-3799). There were few prospective studies existed that the efficacy and toxicity of CapeOx as adjuvant setting in patients undergoing radical resection for their CRLMs. So we conducted this phase II trial to evaluate the safety and efficacy of adjuvant CapeOx for CRLM in 2013. We previously reported safety analysis in ESMO-GI 2019 (Watanabe T, et al.); here we present the survival analysis.
Methods
Patients with undergoing curative resection of CRLM were eligible for this study. Capecitabine 1,000mg/m2 was given orally twice daily for 14 days followed by a 7-days rest; oxaliplatin 130mg/m2 on day1 was given by intravenous infusion. CapeOx were performed up to 8 cycles. The primary endpoint was 3-year relapse-free survival (RFS), while secondary endpoints were overall survival (OS), relative dose intensity and safety. We calculated a sample size at 50 patients based on the threshold and expected 3-year RFS were 30% and 45%, respectively, with a one-sided alpha error of 0.05 and power of 0.80.
Results
This study was closed prematurely due to poor accrual. In total, 27 patients were enrolled from 9 institutions between September 2014 and January 2019. As two patients who did not start protocol treatment because of condition worsening were excluded from this analysis, 25 patients were evaluated. Median age was 64, male/female; 15/10, ECOG PS 0/1; 24/1, sidedness right/left; 8/17, tub1/tub2; 12/13, number of metastases 1∼3/ 4∼; 17/8, Hr0/ HrS/ Hr1/ Hr2/ Hr3; 8/5/7/4/1. The completion rate of protocol treatment was 64%. Relative dose intensity of capecitabine and oxaliplatin were 86.0% and 82.2%, respectively. The reasons for discontinuation were adverse events (28%) and recurrence of cancer (8%). The most frequently reported grade 3-4 adverse events were neutropenia (20%), sensory neuropathy (12%) and leucopenia (8%). One treatment related death was observed because of disseminated intravascular coagulation. With a median follow-up of 50.5 months as of the data cutoff date of January 31, 2022, 3-year RFS was 52% (95% CI 31.2 - 69.2), median RFS was 36.6 months (95% CI 16.1-NA). Only six patients were dead during this study, so overall survival was not reached.
Conclusions
Our data suggested that adjuvant chemotherapy with CapeOx was feasible and tolerable in patients with undergoing curative resection of CRLMs.
Clinical trial identification
UMIN 000013324.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosures
H. Satake: Honoraria (self): Ono pharmaceutical co., ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan Co., Ltd., Merck Bio Pharma Co., Ltd., MSD Co., Ltd., Bayer Co., Ltd., Bristol-Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Sanofi Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Co., Ltd. and Yakult Honsha Co., Ltd.; Research grant / Funding (institution): Ono pharmaceutical co., ltd., Daiichi Sankyo, Takeda Pharmaceutical Co., Ltd., Sanofi, Taiho Pharmaceutical Co., Ltd.. M. Kotaka: Honoraria (self): Chugai pharmaceutical, Lilly. T. Satoh: Honoraria (self): Bristol-Myers, Ono Pharmaceutical, Elli-Lilly, Chugai Pharmazeutical, Daiichi-Sankyo; Research grant / Funding (self): Yakult Honsha, Taiho, Chugai Pharmaceutical; Research grant / Funding (institution): Yakult Honsha, Taiho, Chugai Pharmaceutical. T. Kurata: Honoraria (self): Bristol-Myers Squibb, Ono, Eli Lilly, AstraZeneca, MSD, Pfizer, Nipponkayaku, Chugai; Research grant / Funding (self): Amgen, MSD, AstraZeneca, Takeda, Bristol-Myers Squibb; Research grant / Funding (institution): Novartis, Chugai, Delta-Fly Pharma, Janssen Pharma, Sanofi. All other authors have declared no conflicts of interest.
